Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130010/S002

ENERGYA/TALENTIA ICDs & CRT-Ds, SmartTouch Programmer Software Modules, SmartView Connect App, & RMS

MicroPort CRM S.r.l. · Decision date Nov 25, 2025

FDA DECISIONP130010/S002

What did the FDA approve?

FDA records P130010/S002 as a supplement to PMA P130010, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 25, 2025.

FDA approval order statement

approval for the ENERGYA/TALENTIA family of ICDs and CRT-Ds and associated SmartTouch Programmer software modules, and updates to the Remote Monitoring System.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Nov 25, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P130010/S002
Regulatory pathway
PMA supplement
Product code
NVN
Decision code
APPR
Decision date
Nov 25, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes.

Product code
NVN
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130010/S002 received

    Application receipt date recorded by FDA.

  2. P130010/S004 · Related supplement

    VEGA R45; VEGA R52; VEGA R58; VEGA R45 RE-INTERVENTION KIT; VEGA R58 RE-INTERVENTION KIT; VEGA R45 RE-INTERVENTION KIT

  3. P130010/S002 · FDA decision

    Normal 180 Day Track

  4. P130010/S005 · Related supplement

    VEGA Steroid-Eluting Endocardial Leads (VEGA R45, VEGA R52, and VEGA R58)

Timeline entries are records held by MedtechLedger for P130010. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130010

Explore the linked device profile

Other records with product code NVN

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Cardiac Rhythm Disease ManagementPMA supplementOct 16, 2026FDA
ABBOTT MEDICALPMA supplementOct 9, 2026FDA
Medtronic Cardiac Rhythm Disease ManagementPMA supplementAug 5, 2026FDA
ABBOTT MEDICALPMA supplementJun 26, 2026FDA
IsoFlex LeadsP960030/S085
ABBOTT MEDICALPMA supplementJun 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

MicroPort CRM S.r.l.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Via Crescentino S.N., Saluggia, 13040

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records